Toggle Main Menu Toggle Search

Open Access padlockePrints

Definition of Delayed Cerebral Ischemia After Aneurysmal: Subarachnoid Hemorrhage as an Outcome Event in Clinical Trials and Observational Studies. Proposal of a Multidisciplinary Research Group

Lookup NU author(s): Emeritus Professor David Mendelow

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Background and Purpose-In clinical trials and observational studies there is considerable inconsistency in the use of definitions to describe delayed cerebral ischemia (DCI) after aneurysmal subarachnoid hemorrhage. A major cause for this inconsistency is the combining of radiographic evidence of vasospasm with clinical features of cerebral ischemia, although multiple factors may contribute to DCI. The second issue is the variability and overlap of terms used to describe each phenomenon. This makes comparisons among studies difficult. Methods-An international ad hoc panel of experts involved in subarachnoid hemorrhage research developed and proposed a definition of DCI to be used as an outcome measure in clinical trials and observational studies. We used a consensus-building approach. Results-It is proposed that in observational studies and clinical trials aiming to investigate strategies to prevent DCI, the 2 main outcome measures should be: (1) cerebral infarction identified on CT or MRI or proven at autopsy, after exclusion of procedure-related infarctions; and (2) functional outcome. Secondary outcome measure should be clinical deterioration caused by DCI, after exclusion of other potential causes of clinical deterioration. Vasospasm on angiography or transcranial Doppler can also be used as an outcome measure to investigate proof of concept but should be interpreted in conjunction with DCI or functional outcome. Conclusion-The proposed measures reflect the most relevant morphological and clinical features of DCI without regard to pathogenesis to be used as an outcome measure in clinical trials and observational studies. (Stroke. 2010;41:2391-2395.)


Publication metadata

Author(s): Vergouwen MDI, Vermeulen M, van Gijn J, Rinkel GJE, Wijdicks EF, Muizelaar JP, Mendelow AD, Juvela S, Yonas H, Terbrugge KG, Macdonald RL, Diringer MN, Broderick JP, Dreier JP, Roos YBWEM

Publication type: Article

Publication status: Published

Journal: Stroke

Year: 2010

Volume: 41

Issue: 10

Pages: 2391-2395

Print publication date: 26/08/2010

ISSN (print): 0039-2499

ISSN (electronic): 1524-4628

Publisher: Lippincott Williams & Wilkins

URL: http://dx.doi.org/10.1161/STROKEAHA.110.589275

DOI: 10.1161/STROKEAHA.110.589275


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Niels Stensen Foundation, the Netherlands
Physicians Services Incorporated Foundation
01 EO 0801Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin and Kompetenznetz Schlaganfall)
DFG DR 323/5-1Deutsche Forschungsgemeinschaft
P50 NS035966National Institutes of Health
P50 NS05597701A2National Institutes of Health

Share